Erudio Healtherudio.com
Clinical trial · no report yet · Phase 1
AMELI-01
Study Evaluating Safety and Efficacy of UCART123v1.2 in Patients With Relapsed/Refractory Acute Myeloid Leukemia
- NCT03190278 ↗
- Active, not recruiting
- Cellectis S.A.
- Focused
We haven't built an HCP commentary report on AMELI-01 (UCART123v1.2 in relapsed/refractory acute myeloid leukemia) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on AMELI-01 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 2 | |
| YouTube | 1 |
The trial
ClinicalTrials.gov- Official title
- Phase I, Open Label Dose Escalation and Dose-Expansion Study to Evaluate the Safety, Expansion, Persistence, and Clinical Activity of UCART123 (Allogeneic Engineered T-cells Expressing Anti-CD123 Chimeric Antigen Receptor), Administered in Patients With Relapsed/Refractory Acute Myeloid Leukemia
- Phase
- Phase 1
- Status
- Active, not recruiting
- Conditions
- Relapsed/Refractory Acute Myeloid Leukemia
- Interventions
- UCART123v1.2
- Arms
- Dose Escalation · Experimental
- Enrollment
- 29
- Primary outcomes
- Incidence of adverse events (AE)/serious adverse events (SAE)/Dose Limiting Toxicities (DLT) [Safety and Tolerability]
- Dose escalation and expansion part: Occurrence of DLTs
- Sponsor
- Cellectis S.A.
- Start
- Jun 19, 2017
- Primary completion
- Dec 24, 2024
- Results posted
- No
- Registry record
- NCT03190278 · updated Aug 7, 2025